Japan approved its 39-trillion-yen economic stimulus package on November 22. It does not explicitly state that the drug price revision…
REGULATORY
Japan Approves Janssen’s COVID Jab, Sanofi’s Sutimlimab, Olumiant’s Alopecia Use and More
Japan health ministry approved a batch of new medicines and indications on June 20 including Janssen Pharmaceutical’s COVID-19 vaccine Jcovden and Sanofi’s anti-C1s monoclonal antibody Enjaymo (sutimlimab). Jcovden, a recombinant vector vaccine, has now become the fifth jab approved in…
To read the full story
Related Article
- Chuikyo OKs Lagevrio, Voxzogo, Enjaymo, and More for August Listing, BioMarin Med with Biggest Peak Sales Outlook
August 10, 2022
- MHLW Panel Endorses Sanofi’s Sutimlimab as Japan’s First CAD Therapy
June 3, 2022
- Japan Panel OKs Taiho’s GIST Med, ViiV/Janssen’s HIV Combo and More for Approval
May 31, 2022
- Janssen’s COVID-19 Vaccine in Line for Japan Approval, No Supply Deal Signed
May 31, 2022
REGULATORY
- Opposition DPP Leader Pledges to Go Full Throttle on Ending Off-Year Revisions
December 3, 2024
- Qalsody, Zepbound, Zeposia Inch Closer to Japan Approval with Panel OK
December 3, 2024
- LDP Pharma Study Group Renews Call for Ditching Off-Year Revisions
December 3, 2024
- Japan Cabinet OKs Extra Budget, 44 Billion Yen for Pharma Measures
December 2, 2024
- Pharma Industry Makes Plea to Komeito to Scrap Off-Year Revisions
December 2, 2024
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…